23 studies found for:    Open Studies | "Sarcoma, Kaposi"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Pomalidomide for Kaposi Sarcoma in People With or Without HIV
Conditions: Kaposi Sarcoma;   Sarcoma, Kaposi
Intervention: Drug: Pomalidomide
2 Not yet recruiting Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
Conditions: AIDS-related Kaposi Sarcoma;   HIV Infection;   Recurrent Kaposi Sarcoma
Interventions: Drug: gamma secretase inhibitor PF-03084014;   Other: pharmacological study;   Other: laboratory biomarker analysis
3 Recruiting A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
Conditions: Kaposi's Sarcoma;   HIV+;   HIV Positive;   AIDS
Intervention: Drug: aldoxorubicin
4 Unknown  Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Condition: Kaposi´s Sarcoma
Intervention: Drug: Bevacizumab
5 Recruiting A Study of Selumetinib in Patients With Kaposi's Sarcoma
Condition: AIDS-related Kaposi's Sarcoma
Intervention: Drug: Selumetinib
6 Recruiting Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe
Conditions: Kaposi Sarcoma (KS);   HIV
Intervention: Other: KS structured clinical care training
7 Recruiting Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging
Condition: Kaposi's Sarcoma
Intervention: Drug: Tc 99m tilmanocept
8 Recruiting Assessment of Blood Vessel Density in Kaposi s Sarcoma Lesions
Condition: Kaposi's Sarcoma
Intervention:
9 Recruiting Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
10 Recruiting Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
Conditions: HIV-1 Infection;   Kaposi's Sarcoma
Interventions: Drug: efavirenz/emtricitabine/tenofovir disoproxil fumarate;   Drug: etoposide
11 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: DEC-205-NY-ESO-1 fusion protein vaccine;   Drug: sirolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Recruiting 124I-FIAU Imaging in EBV and KSHV Associated Cancers
Conditions: Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Kaposi's Sarcoma;   Gastric Cancer;   Nasopharyngeal Cancer
Interventions: Other: FIAU-PET-CT scans;   Other: FIAU-PET-CT scan
13 Not yet recruiting Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
Conditions: Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Kaposi Sarcoma;   Gastric Cancer;   Nasopharyngeal Cancer;   EBV;   Castleman Disease
Intervention: Drug: Nelfinavir
14 Recruiting Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Conditions: HIV;   Kaposi's Sarcoma;   Lymphomas;   Multicentric Castleman's Disease;   Primary Effusion Lymphoma
Intervention:
15 Recruiting History of the KSHV Inflammatory Cytokine Syndrome (KICS)
Conditions: KSHV Inflammatory Cytokine Syndrome (KICS);   KSHV;   HHV-8
Interventions: Drug: Zidovudine/Valgancyclovir;   Drug: Rituximab/Liposoma Doxorubicin
16 Recruiting Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Conditions: Castleman Disease;   Castleman's Disease;   Giant Lymph Node Hyperplasia
Interventions: Drug: Zidovudine;   Drug: Tocilizumab;   Drug: Valganciclovir
17 Not yet recruiting A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
Conditions: Kaposiform Hemangioendothelioma (KHE);   Kasabach-Merritt Syndrome;   Tufted Angioma
Interventions: Drug: Vincristine;   Drug: Sirolimus
18 Recruiting Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bortezomib;   Drug: carboplatin;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Genetic: polymerase chain reaction;   Genetic: western blotting
19 Unknown  Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Condition: Cancer
Interventions: Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: cryosurgery
20 Recruiting Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
Conditions: Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease;   Primary Effusion Lymphoma
Interventions: Drug: Pomalidomide;   Drug: Rituximab;   Drug: Prednisone;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Indicates status has not been verified in more than two years